Ovarian cancer study offers new strategies
The study, headed by Peter MacCallum Cancer Centre (Peter Mac) researchers, involved more than 1000 women with non-mucinous ovarian carcinoma.
The findings could lead to better targeted chemotherapy and determine whether patients receive genetic testing, its authors say.
The researchers found that women carrying BRCA1 and BRCA2 mutations more often responded to platin and nonplatin-based drug therapy than women without the mutations and tended to survive longer, co-author Professor David Bowtell said.
About half the women with the mutations did not